58 related articles for article (PubMed ID: 27693091)
1. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
[TBL] [Abstract][Full Text] [Related]
2. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
Sonpavde G; Pond GR; Fougeray R; Choueiri TK; Qu AQ; Vaughn DJ; Niegisch G; Albers P; James ND; Wong YN; Ko YJ; Sridhar SS; Galsky MD; Petrylak DP; Vaishampayan UN; Khan A; Vogelzang NJ; Beer TM; Stadler WM; O'Donnell PH; Sternberg CN; Rosenberg JE; Bellmunt J
Eur Urol; 2013 Apr; 63(4):717-23. PubMed ID: 23206856
[TBL] [Abstract][Full Text] [Related]
3. RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A Multicenter Real-World Study in China.
Chen J; Wang M; Qi X; Long H; Qi N; Wu L; Ke M; Shao S; Li P; Chen Y; Wang W; Zhu S; Qi X; Li G
Clin Genitourin Cancer; 2024 Jun; 22(3):102093. PubMed ID: 38762350
[TBL] [Abstract][Full Text] [Related]
4. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
Shindo T; Hashimoto K; Fujino K; Takahashi A; Hotta H; Maeda T; Kunishima Y; Fukuta F; Ito N; Wanifuchi A; Kato R; Okada M; Matsukawa M; Horita H; Takayanagi A; Kobayashi K; Tanaka T; Masumori N
World J Urol; 2024 May; 42(1):307. PubMed ID: 38722418
[TBL] [Abstract][Full Text] [Related]
5. Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Kondo T
Int J Urol; 2024 May; 31(5):560-561. PubMed ID: 38424666
[No Abstract] [Full Text] [Related]
6. Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
Ishihara H; Takagi T
Int J Urol; 2024 May; 31(5):559-560. PubMed ID: 38366784
[No Abstract] [Full Text] [Related]
7. Surgical Management of Metastatic Adrenocortical Carcinoma.
Passman JE; Amjad W; Ginzberg SP; Soegaard Ballester JM; Finn C; Wachtel H
World J Surg; 2024 Jan; 48(1):110-120. PubMed ID: 38463201
[TBL] [Abstract][Full Text] [Related]
8. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
Tanabe K; Kobayashi S; Maezawa Y; Ishihara K; Inoue N; Izumi K; Fujiwara M; Toide M; Yamamoto T; Uehara S; Araki S; Inoue M; Takazawa R; Numao N; Ohtsuka Y; Tanaka H; Yoshida S; Fujii Y
Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38833113
[TBL] [Abstract][Full Text] [Related]
9. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
Wong P; Wisneski AD; Tsai KK; Chang TT; Hirose K; Nakakura EK; Daud AI; Maker AV; Corvera CU
World J Surg Oncol; 2024 Mar; 22(1):77. PubMed ID: 38468341
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.
Niegisch G; Grimm MO; Hardtstock F; Krieger J; Starry A; Osowski U; Guenther S; Deiters B; Maywald U; Wilke T; Kearney M
Future Oncol; 2024 Apr; ():1-16. PubMed ID: 38647011
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated With Prescription of Systemic Therapy in Real-world Patients With Metastatic Renal Cell Cancer Managed in a Rural Region.
Nieder C; Stanisavljevic L; Haukland EC
Cancer Diagn Progn; 2024; 4(3):250-255. PubMed ID: 38707739
[TBL] [Abstract][Full Text] [Related]
12. Correction to: Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.
Maráz A; Nagy B; Macher T; Jeskó J; Tischler E; Csongvai C; Kearney M
Adv Ther; 2024 Feb; 41(2):881-882. PubMed ID: 38070042
[No Abstract] [Full Text] [Related]
13. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Sharma P; Callahan MK; Bono P; Kim J; Spiliopoulou P; Calvo E; Pillai RN; Ott PA; de Braud F; Morse M; Le DT; Jaeger D; Chan E; Harbison C; Lin CS; Tschaika M; Azrilevich A; Rosenberg JE
Lancet Oncol; 2016 Nov; 17(11):1590-1598. PubMed ID: 27733243
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
15. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
16. Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma.
Sonpavde GP; Mariani L; Lo Vullo S; Raggi D; Giannatempo P; Bamias A; Crabb SJ; Bellmunt J; Yu EY; Niegisch G; Vaishampayan UN; Theodore C; Berthold DR; Srinivas S; Sridhar SS; Plimack ER; Rosenberg JE; Powles T; Galsky MD; Necchi A
J Urol; 2018 Dec; 200(6):1207-1214. PubMed ID: 30012366
[TBL] [Abstract][Full Text] [Related]
17. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
18. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Szabados B; van Dijk N; Tang YZ; van der Heijden MS; Wimalasingham A; Gomez de Liano A; Chowdhury S; Hughes S; Rudman S; Linch M; Powles T
Eur Urol; 2018 Feb; 73(2):149-152. PubMed ID: 28917596
[TBL] [Abstract][Full Text] [Related]
19. Serum lactate dehydrogenase level predicts the prognosis in bladder cancer patients.
Gu S; Yang C
BMC Urol; 2023 Apr; 23(1):65. PubMed ID: 37098538
[TBL] [Abstract][Full Text] [Related]
20. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
Taguchi S; Kawai T; Nakagawa T; Miyakawa J; Kishitani K; Sugimoto K; Nakamura Y; Kamei J; Obinata D; Yamaguchi K; Kaneko T; Yoshida K; Yamamoto S; Kakutani S; Kanazawa K; Sugihara Y; Tokunaga M; Matsumoto A; Uemura Y; Akiyama Y; Yamada Y; Sato Y; Yamada D; Enomoto Y; Nishimatsu H; Ishikawa A; Tanaka Y; Nagase Y; Fujimura T; Fukuhara H; Takahashi S; Kume H
Int J Urol; 2022 Dec; 29(12):1462-1469. PubMed ID: 35996761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]